Why the study?
Does aspirin effectively inhibit platelet aggregation and reduce 11-dehydro thromboxane B2 levels in healthy individuals?
Population
Healthy individuals
Comparison
Aspirin vs Pre-aspirin baseline
Design
Cohort
Authors
Loading...
Supports minimal true aspirin resistance in healthy subjects; leaves open PFA-100 utility and dose-response questions for patients.
Does aspirin effectively inhibit platelet aggregation and reduce 11-dehydro thromboxane B2 levels in healthy individuals?
Full biological resistance to aspirin is unlikely in healthy subjects, though apparent non-response on PFA-100 with low-dose aspirin can occur and may be overcome with higher doses.
Gónzález‐Conejero et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: